Overview

A Study of CCX140-B in Subjects With FSGS

Status:
Completed

Trial end date:
2020-02-19

Target enrollment:

Participant gender:

Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia

Phase:

Phase 2

Details

Lead Sponsor:

ChemoCentryx

Collaborator:

Medpace, Inc.